Alnylam's Liver Cancer RNAi Program Enters The Clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alnylam Pharmaceuticals's ALN-VSP RNA interference program has begun clinical trials in patients with advanced liver cancers, the Cambridge-MA.-based biotech said April 3